Amphastar Pharmaceuticals (AMPH) Return on Equity (2016 - 2025)

Amphastar Pharmaceuticals has reported Return on Equity over the past 12 years, most recently at 0.17% for Q4 2025.

  • Quarterly results put Return on Equity at 0.17% for Q4 2025, down 6.0% from a year ago — trailing twelve months through Dec 2025 was 0.17% (down 6.0% YoY), and the annual figure for FY2025 was 0.17%, down 7.0%.
  • Return on Equity for Q4 2025 was 0.17% at Amphastar Pharmaceuticals, up from 0.15% in the prior quarter.
  • Over the last five years, Return on Equity for AMPH hit a ceiling of 0.23% in Q4 2024 and a floor of 0.07% in Q4 2023.
  • Median Return on Equity over the past 5 years was 0.05% (2021), compared with a mean of 0.07%.
  • Biggest five-year swings in Return on Equity: fell -25bps in 2023 and later grew 30bps in 2024.
  • Amphastar Pharmaceuticals' Return on Equity stood at 0.15% in 2021, then crashed by -144bps to 0.07% in 2022, then fell by -2bps to 0.07% in 2023, then surged by 430bps to 0.23% in 2024, then fell by -26bps to 0.17% in 2025.
  • The last three reported values for Return on Equity were 0.17% (Q4 2025), 0.15% (Q3 2025), and 0.19% (Q2 2025) per Business Quant data.